ASX:IMU Imugene (IMU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Imugene Stock (ASX:IMU) 30 days 90 days 365 days Advanced Chart Get Imugene alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume12.70 million shsAverage VolumeN/AMarket Capitalization$290.84 millionP/E RatioN/ADividend Yield3.03%Price TargetN/AConsensus RatingN/A Company OverviewImugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.Read More… Receive IMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter. Email Address IMU Stock News HeadlinesImugene Appoints Dr. John Byon as Chief Medical Officer to Advance Cancer ImmunotherapyMay 29 at 9:09 PM | tipranks.comImugene Issues Addendum to Extraordinary General Meeting NoticeMay 27 at 4:51 AM | tipranks.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.May 30, 2025 | Brownstone Research (Ad)Imugene Limited Announces Extraordinary General Meeting for June 2025May 26, 2025 | tipranks.comHotCopper Highlights Week 21: Trump jump for uranium; James Hardie, Imugene & moreMay 23, 2025 | msn.comImugene Limited Issues New Equity Securities as Part of Employee Incentive SchemeMay 23, 2025 | tipranks.comImugene Limited Announces Cessation of SecuritiesMay 21, 2025 | tipranks.comHotCopper Highlights, Week 18: Imugene's letter to investors; Dimerix & DatelineMay 2, 2025 | msn.comSee More Headlines IMU Stock Analysis - Frequently Asked Questions How were Imugene's earnings last quarter? Imugene Limited (ASX:IMU) issued its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter. Imugene had a negative net margin of 1,855.22% and a negative trailing twelve-month return on equity of 95.62%. What other stocks do shareholders of Imugene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imugene investors own include Meta Platforms (META), NVIDIA (NVDA), Precision BioSciences (DTIL), Fortescue (FMG), Teladoc Health (TDOC), Viralytics (VRACY) and Whitehaven Coal (WHC). Company Calendar Last Earnings2/28/2019Today5/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:IMU CIKN/A Webwww.imugene.com Phone61 3 9824 5254FaxN/AEmployees110Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.68 million Net Margins-1,855.22% Pretax MarginN/A Return on Equity-95.62% Return on Assets-50.88% Debt Debt-to-Equity Ratio1.31 Current Ratio3.86 Quick Ratio15.17 Sales & Book Value Annual Sales$4.97 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.75 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares7,570,000,000Free FloatN/AMarket Cap$290.84 million OptionableNot Optionable Beta3.34 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (ASX:IMU) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Imugene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.